Prime Medicine, Inc.

Prime Medicine, Inc.

PRME·NASDAQ

$3.21

-2.2%
HealthcareBiotechnology

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$579.78M
EPS-1.3500
P/E Ratio-2.57
Earnings Date08/06/2026

prme

Long Term Debt

Last Annual Value

108.29M

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Prime Medicine, Inc.

Prime Medicine, Inc. Competitors Analysis of Long Term Debt

PRME · NASDAQ
CompanyLong Term Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
108.29M
N/AN/AN/A 
PROK logo
ProKidney Corp.
NASDAQ:PROK
0.00
N/AN/AN/A
9.71M
1.3%N/A2.9%
SEPN logo
Septerna, Inc.
NASDAQ:SEPN
21.41M
N/AN/AN/A
0.00
N/AN/AN/A
46.38M
17.4%N/AN/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
0.00
N/AN/AN/A
30.14M
-61.3%-43.5%N/A
5.34M
N/AN/AN/A
89.05M
N/AN/AN/A
593.00K
N/AN/AN/A
Prime Medicine, Inc.

Prime Medicine, Inc. Fair Value Envelope

PRME · NASDAQ

Our analysis suggests that PRME has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.21, this represents a potential HIDDEN relative to our calculated worth for Prime Medicine, Inc..

Intrinsic Value
Current Price: $3.21